Cellectis Inc.

Good morning, everyone, and welcome to the selected second quarter 2022 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. Please be aware that today's conference call is being recorded. I'd now like to introduce the first speaker, Artis Drill, Chief Business Officer. You may begin.

Good morning. and welcome everyone to SELECTIS' second quarter 2022 corporate update and financial results conference call. Joining me on the call today with prepared remarks are Dr. André Choulika, our Chief Executive Officer, and Dr. Bing Wang, our Chief Financial Officer. Dr. Brownstein is absent for today's call, so I will be speaking about our CAR-T program updates. Yesterday evening, Selectis filed its interim reports and issued a press release reporting its financial results for the second quarter and six-month period ended June 30th, 2022. The report and press release are available on our website at selectis.com. As a reminder, we will make statements regarding Selectis Financial Outlook in addition to its manufacturing, regulatory, and product development plan. These forward statements which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the SEC and the financial reports, including the management reports, for the year ending on December 31st, 2021, and subsequent filings selected makes with the Securities Exchange Commission from time to time. I would now like to turn the call over to Andre.

Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. Rectis continues to make progress in enrolling patients in our three sponsored phase one dose escalation trials and take notable steps forward with our preclinical data and programs. This week, we're proud to announce the FDA clearance of our investigational new drug application for UCAR20x22, our product candidate, being developed for patients with relapsed or refractory nub Hodgkin's lymphoma. The UCAR20x22 program is very exciting. and will be selected as first dual targeting allogenic CAR T cell product candidate to enter clinical trial. Targeting CD20 and CD22, both validated targets in B-cell malignancies, has the potential to enhance tumor cell killing and increases the breadth of antigen targeting. These advantages may increase the addressable patient population and provide a potential therapeutic alternative to CD19-directed therapy. UCAR-T 20x22 will also be our first product candidate with fully integrated in-house development, showcasing our transformation into an end-to-end cell and gene therapy company, from discovery and product development and transfer into GMP manufacturing and clinical development. This quarter, we're also pleased to publish research data on our novel immune-evasive universal CAR T-cell in nature communication following our oral presentation at the American Society of Cell and Gene Therapy. These novel immune-evasive universal CAR T-cells are very promising, and they may address the main challenges of allogenic CAR T-cells. The first of which is depletion by the host immune system via the host versus graft reaction, followed by enabling the proliferation of cells without attacking host tissue via the graft versus host reaction. While the prevention of graft versus host reaction can be readily addressed by an inactivation of T cell receptor, T alpha expression in CAR T cells, our engineering approach could enable the universal CAR T cell to become transiently invisible to natural careless cells and allogenic T cells, allowing them to eradicate tumor cells before being rejected by the patient immune system. This could enable the broad use of universal CAR T cell in allogenic settings for the benefit of a wider population of patients. This quarter, We also continue to expand our incredible leadership team. Selectives announced that during our annual shareholders meeting that Axel Sven Malkimus and Dr. Donald Bergstrom have been appointed as director for the company's board of director. We are very pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkimus to the Selectives Board. There are both seasoned leaders with the healthcare industry who brings decades of experience in both the healthcare and financial services sector to select us. We're confident that they will provide meaningful and valued perspectives as we continue to progress toward becoming one of the few end-to-end cell and gene therapy companies. Now, I would like to turn the call over to Arthur Strill, our Chief Business Officer who will give an overview of the three sponsored clinical trials and three clinical product pipelines. Arthur, please go ahead.